Eli Lilly and Company (NYSE:LLY) Trading Up 3.7% – Should You Buy?

Eli Lilly and Company (NYSE:LLY) shares rose 3.7% on Tuesday . The company traded as high as $1,228.47 and last traded at $1,227.1070. Approximately 2,446,088 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 3,097,944 shares. The stock had previously closed at $1,183.16.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity portfolio momentum remains the primary catalyst. Lilly’s Zepbound sales reportedly jumped 46%, while its broader GLP-1 portfolio outpaced Novo Nordisk’s in the latest quarter. Investors are also focused on retatrutide and the potential for oral obesity medicines to expand the addressable market. How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
• Positive Sentiment: Strong financial results reinforce the growth narrative. Lilly’s latest quarter produced $8.38 in adjusted earnings per share on $22.97 billion of revenue, exceeding consensus estimates, while revenue increased 47.7% year over year. Fiscal 2026 earnings guidance remains $35.50 to $36.50 per share.
• Positive Sentiment: Analysts see additional long-term upside. Commentary describes Lilly as a top growth stock and highlights its potential to become a leading pharmaceutical company in oral GLP-1 therapies. The consensus rating remains “Moderate Buy,” with several firms maintaining or raising price targets. Stock Forecast: The Market is Sleeping on Eli Lilly’s Next $1 Trillion Opportunity
• Positive Sentiment: Pipeline expansion adds diversification. Lilly advanced neuroscience and oral-drug programs through new formulation and Phase 1 studies, and announced partnerships involving OmniAb’s ion-channel program and AlzeCure’s central-nervous-system candidates. These efforts could support future growth beyond obesity treatments. OmniAb Enters Collaboration and License Agreement with Eli Lilly
• Neutral Sentiment: Early-stage clinical updates provide limited immediate financial impact. Study completions for lepodisiran and LY4086940, along with a LY4065967 formulation study, indicate pipeline progress but do not yet provide efficacy or approval data.
• Negative Sentiment: Competition and valuation temper the bullish case. Novo Nordisk reportedly gained an early lead in oral obesity treatments, and Pfizer is developing a potential competing therapy. With LLY valued above $1 trillion and trading at a premium earnings multiple, any disappointment in clinical execution, pricing or demand could pressure the shares.
• Negative Sentiment: An insider sale is a minor sentiment headwind. EVP Patrik Jonsson sold 6,500 shares worth approximately $7.6 million under a pre-arranged Rule 10b5-1 plan, making the transaction less concerning than discretionary selling. SEC Insider Transaction Filing

Analysts Set New Price Targets

A number of brokerages have recently commented on LLY. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. BMO Capital Markets reiterated an “outperform” rating and issued a $1,400.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Barclays upped their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. Finally, Guggenheim lifted their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company Stock Up 4.5%

The stock’s fifty day moving average price is $1,176.04 and its 200 day moving average price is $1,056.96. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.21 trillion, a P/E ratio of 42.97, a price-to-earnings-growth ratio of 1.45 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the business earned $6.31 earnings per share. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last quarter. 0.14% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the company. Willner & Heller LLC increased its stake in shares of Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after buying an additional 9 shares during the period. Aspiring Ventures LLC lifted its holdings in Eli Lilly and Company by 3.7% in the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after buying an additional 9 shares during the period. Wealthspan Partners LLC boosted its position in Eli Lilly and Company by 0.4% during the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after acquiring an additional 9 shares in the last quarter. Navigoe LLC boosted its position in Eli Lilly and Company by 8.7% during the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock valued at $135,000 after acquiring an additional 9 shares in the last quarter. Finally, Tanager Wealth Management LLP grew its holdings in shares of Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after acquiring an additional 10 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.